Results 1 to 10 of about 96,194 (242)

The promises of quantitative systems pharmacology modelling for drug development

Computational and Structural Biotechnology Journal, 2016
Recent growth in annual new therapeutic entity (NTE) approvals by the U.S. Food and Drug Administration (FDA) suggests a positive trend in current research and development (R&D) output.
V.R. Knight-Schrijver, V. Chelliah, L. Cucurull-Sanchez, N. Le Novère   +3 more
doaj   +5 more sources

Quantitative systems pharmacology in the age of artificial intelligence [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2023
Benjamin Ribba
doaj   +4 more sources

A Review of Quantitative Systems Pharmacology Models of the Coagulation Cascade: Opportunities for Improved Usability

Pharmaceutics, 2023
Despite the numerous therapeutic options to treat bleeding or thrombosis, a comprehensive quantitative mechanistic understanding of the effects of these and potential novel therapies is lacking. Recently, the quality of quantitative systems pharmacology (
Douglas Chung, Suruchi Bakshi, Piet H. van der Graaf   +2 more
doaj   +3 more sources

Quantitative systems pharmacology model of B cell immune response in mouse [PDF]

Frontiers in Immunology
B cell-mediated immunity plays a crucial role in long-term humoral protection. However, dysregulation of B cell development and differentiation may lead to the persistence of autoreactive clones, contributing to autoimmune diseases.
Yaroslav Ugolkov, Yaroslav Ugolkov, Yaroslav Ugolkov, Alina Volkova, Alina Volkova, Gabriel Helmlinger, Kirill Peskov, Kirill Peskov, Kirill Peskov, Victor Sokolov, Victor Sokolov   +10 more
doaj   +2 more sources

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies [PDF]

CPT: Pharmacometrics & Systems Pharmacology
The effectiveness of Bruton tyrosine kinase (BTK) inhibitors is influenced by the level of BTK occupancy in target tissues. In randomized phase 3 studies, progression‐free survival (PFS) with zanubrutinib was superior to ibrutinib, whereas acalabrutinib ...
Oleg Demin Jr, Ying Ou, Galina Kolesova, Dmitry Shchelokov, Alexander Stepanov, Veronika Musatova, Sri Sahasranaman, Yating Zhao, Xiangyu Liu, Zhiyu Tang, William D. Hanley   +10 more
doaj   +2 more sources

Quantitative systems pharmacology of the eye: Tools and data for ocular QSP [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2023
Good eyesight belongs to the most‐valued attributes of health, and diseases of the eye are a significant healthcare burden. Case numbers are expected to further increase in the next decades due to an aging society.
Lars Kuepfer, Georg Fuellen, Thomas Stahnke   +2 more
doaj   +2 more sources

Quantitative Systems Pharmacology Modeling Amid the Rise of Agentic AI [PDF]

CPT: Pharmacometrics & Systems Pharmacology
James Lu, Rajat Desikan
doaj   +2 more sources

Quantitative systems modeling approaches towards model-informed drug development: Perspective through case studies

Frontiers in Systems Biology, 2023
Quantitative systems pharmacology (QSP) modeling has become an increasingly popular approach impacting our understanding of disease mechanisms and helping predict patients’ treatment responses to facilitate study design or development go/no-go decisions.
Meghna Verma, Louis Gall, Jacopo Biasetti, Giovanni Y. Di Veroli, Cesar Pichardo-Almarza, Megan A. Gibbs, Holly Kimko   +6 more
doaj   +1 more source

Homeostasis, injury, and recovery dynamics at multiple scales in a self-organizing mouse intestinal crypt

eLife, 2023
The maintenance of the functional integrity of the intestinal epithelium requires a tight coordination between cell production, migration, and shedding along the crypt–villus axis.
Louis Gall, Carrie Duckworth, Ferran Jardi, Lieve Lammens, Aimee Parker, Ambra Bianco, Holly Kimko, David Mark Pritchard, Carmen Pin   +8 more
doaj   +1 more source

Broadening our understanding of genetic risk for scleroderma/systemic sclerosis by querying the chromatin architecture surrounding the risk haplotypes

BMC Medical Genomics, 2021
Background Genetic variants in the human leukocyte antigen (HLA) locus contribute to the risk for developing scleroderma/systemic sclerosis (SSc). However, there are other replicated loci that also contribute to genetic risk for SSc, and it is unknown ...
Kerry E. Poppenberg, Vincent M. Tutino, Evan Tarbell, James N. Jarvis   +3 more
doaj   +1 more source